Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126470) titled 'Target for alternative HBV patients in real world practice in China (TREATALL study)' on June 9.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Hebei Medical University Third Hospital
Condition:
Chronic Hepatitis B
Intervention:
Liver cirrhosis group:None
Combined Metabolic Syndrome group:None
HBV DNA positive initial treatment group:None
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-06-10
Target Sample Size: Liver cirrhosis group:655;Combined Metabolic Syndrome group:655;HBV DNA positive initial treatment group:655;Renal insufficiency group:65...